Why Eli Lilly Stock is the ‘Nvidia’ of GLP-1 Meds
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
- Latest
- Trending
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Eli Lilly launches affordable Zepbound vials, easing supply issues and competing with Novo Nordisk's weight-loss drug.
Discover how Novo Nordisk, Moderna, and Regeneron are poised for growth amidst market volatility with innovative biotech solutions.
Discover promising biotech stocks with expert insights on market trends and innovative drugmakers worth your investment.
Disney's streaming business posts its first profit, driving shares up and pushing major indices into positive territory.
Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
JPMorgan predicts continued outperformance of defensive sectors like Utilities, Real Estate, and Staples into Q3, favoring them over cyclical stocks.
Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.